Translational Immunology in Kidney Disease - ISN Nexus Symposium 2016

ISN's Nexus Symposia strongly support the translational approach to disease management and have a clear objective of providing physicians with new insights and hands-on information that they can instantly apply. The ISN Nexus Symposia format allows for focused and in-depth discussions, networking and exchange of ideas among scientists and physicians who recognize the luxury of focusing on one specific topic that has strong clinical relevance. The translational nature of the content is amplified by an inter-speciality approach which provides an additional viewpoint and increased appreciation and understanding of the complexities of a disease.

Drug development has dramatically improved disease outcomes in most medical disciplines, not so in nephrology. Despite enormous research efforts done by the basic science kidney research community only few drug targets finally could be successfully validated and developed into innovative drugs in clinical practice for the benefit of patients with kidney disease. There is an urgent need to improve translational science and successful drug development in the field of nephrology. It is part of the ISN's mission to support this process.

This Nexus meeting will bring together basic and clinical scientists as well as industry partners to present and discuss the future of immunosuppressive and immunomodulatory drugs in kidney disease. How to select the best molecular targets and to overcome the problems in translational research, the limitations in clinical trial design, and the implementation of novel drugs in clinical practice will be discussed.

They are invite scientists and clinicians of the fields of nephrology, immunology, rheumatology, pharmacology as well as industry partners working on drug development programs for kidney diseases. Its them that have to build the nephrology of the future, so join us in Berlin to participate and support that interdisciplinary mission.

Prices:
ISN Members (Early Registration): EUR 400
New ISN Members Joining (Early Registration): EUR 560
Non-members (Early Registration): EUR 600
Pharmaceutical Company (Early Registration): EUR 2000
ISN Members (Regular Rate): EUR 500
New ISN Members Joining (Regular Rate): EUR 660
Non-members (Regular Rate): EUR 700
Pharmaceutical Company (Regular Rate): EUR 2600
ISN Members (Late Rate): EUR 600
New ISN Members Joining (Late Rate): EUR 760
Non-members (Late Rate): EUR 800
Pharmaceutical Company (Late Rate): EUR 3000

Speakers: Hans-Joakim Anders (Germany), Paul Brunetta (USA), Tak Mao Chan (Hong Kong/China), Anne Davidson (USA), Dick De Zeeuw (The Netherlands), Jeremy Duffield (USA), Dirk Eulberg (Germany), Jurgen Floege (Germany), Loic Guillevin (France), Steven Holdsworth (Australia), Jeremy Hughes (United Kingdom), David Jayne (United Kingdom), Ralph Kettritz (Germany), Larissa Lapteva (USA), Adeera Levin (Canada), Jinhua Li (Australia), Elizabeth Lightstone (United Kingdom), Matthias Mack (Germany), Eoin McKinney (United Kingdom), Charles Pusey (United Kingdom), Chaim Putterman (USA), Ton Rabelink (The Netherlands), Andreas Radbruch (Germany), Mary Reilly (USA), Marlies Reinders (The Netherlands), Giuseppe Remuzzi (Italy), Brad Rovin (USA), Piero Ruggenenti (Italy), Steven Sacks (United Kingdom), Thomas Schall (USA), Kumar Sharma (USA), Rolf Stahl (Germany), Yasuhiko Tomino (Japan), Steve Woodle (USA), Ming-hui Zhao (China)